I don't know about you guys, but I am

2,864 Views | 3 Replies | Last: 6 yr ago by Nostradawgus
Monkdawg
How long do you want to ignore this user?
very happy we are going into next season with a full compliment of guards. Under Fox, we played 1 or 2 guards short for numerous seasons. That left us vulnerable to injury and pressure. I still think we don't have enough PG types to truly get the most out of our team (we really only have 1 true PG - Hightower), but it won't kill us in the coming season. To play at a faster pace, you must have real PGs, not reasonable facsimiles thereof. Having combos running point is not the best thing. They don't have PG instincts, particularly in the open court. Still, we should be able to score better from the perimeter, another thing that having too few guards in general makes very difficult. Crean has pointed out that we often took highly contested shots, which would generally be shots in the post. He has also noted how little movement we had on offense. But that was by design. Fox's system didn't call for movement and encouraged taking contested shots in the post (when Maten is your best player). Fox's offense against both man and zone often had players stuck in place and easy to defend. I'm looking forward to what Crean's offenses look like.
Champ
How long do you want to ignore this user?
How many C / PF's Crean sign this year
Monkdawg
How long do you want to ignore this user?
If you mean the '18 class, just 1 - Ngumeze.
blackmountaindawg
How long do you want to ignore this user?
We have good roster mix for the '17-18 season, but the senior class is post heavy, and when they move on we will be left with 3 returning posts for '18-19. The '19 class would be a good class for a grad-transfer post. That would give CTC a 3rd scholly for the 2020 class.
Nostradawgus
How long do you want to ignore this user?
We now have a wealth of shooters.

Crean needs to turn more than one into a maker.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.